Progress of innovative drug research in China
10.11665/j.issn.1000-5048.2026042802
- VernacularTitle:我国创新药研究新进展
- Author:
Yuhang WANG
1
;
Bin DI
;
Yong YANG
;
Cheng JIANG
Author Information
1. 中国药科大学药学院, 南京 211198;中国药科大学基础医学与临床药学学院, 南京 211198
- Publication Type:Journal Article
- Keywords:
innovative drugs;
new drug research and development;
chemical drugs;
biological products
- From:
Journal of China Pharmaceutical University
2026;57(3):275-287
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, China’s capacity for new drug research and development has been significantly strengthened, with major breakthroughs across multiple therapeutic areas, including cancer, autoimmune diseases, and metabolic disorders. An increasing number of domestically developed innovative drugs have been approved for marketing, gradually establishing a competitive position against imported drugs and expanding into global markets. This article systematically reviews the latest research progress of Class 1 innovative drugs in China from 2023 to 2024, categorizes representative approved drugs by therapeutic area, summarizes the clinical advantages and characteristics of representative drugs approved, analyzes in depth the current development trends of and challenges for China’s innovative pharmaceutical industry, and explores future directions, aiming to provide some reference for innovative drug research, industrial development, and policy-making in China.
